ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026
Enoxaparin Dosing and Target anti-Factor Xa Achievement in Infants by Postmenstrual Age.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCurrently, there is little literature delineating the optimal doses of enoxaparin required within the premature and infant populations. This study aims to assess the enoxaparin dose needed to achieve therapeutic anti-factor Xa concentrations through stratifying infants by postmenstrual age (PMA).
methodsThis is a retrospective, single-center, cohort study of infants who received at least 1 dose of treatment enoxaparin between September 2020 and September 2023. The primary endpoint was dose required to achieve therapeutic anti-factor Xa concentrations stratified by PMA group. Secondary endpoints were time in therapeutic range, average dose throughout course, number of dose adjustments and rates of bleeding and acute kidney injury.
resultsEighty-four patient encounters met inclusion criteria in which there were 108 unique courses of enoxaparin. Subjects were primarily of term gestation (median 37.5 weeks) and admitted for congenital heart disease (79.8%). The dose needed to achieve the first therapeutic anti-factor Xa concentration by course was significantly different based on PMA (p < 0.001): median 1.80 mg/kg (IQR 1.53-2.20 mg/kg) with PMA < 40 weeks, 1.64 mg/kg (IQR 1.55-1.77 mg/kg) with PMA 40 to 44 weeks and 1.49 mg/kg (IQR 1.19-1.74 mg/kg) with PMA >44 weeks. The median time in therapeutic range was 71% (IQR 53%-90%) per course. Overall, there were 6 cases of bleeding (5 were classified as minimal and none as severe).
conclusionsSubjects with lower postmenstrual ages required significantly higher enoxaparin doses to achieve therapeutic anti-factor Xa concentrations. Postmenstrual age may provide a more appropriate basis for dosing enoxaparin compared with gestational age and postnatal age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.